JP2012525397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525397A5 JP2012525397A5 JP2012508606A JP2012508606A JP2012525397A5 JP 2012525397 A5 JP2012525397 A5 JP 2012525397A5 JP 2012508606 A JP2012508606 A JP 2012508606A JP 2012508606 A JP2012508606 A JP 2012508606A JP 2012525397 A5 JP2012525397 A5 JP 2012525397A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- item
- deficiency
- formulation
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 59
- 238000009472 formulation Methods 0.000 claims description 53
- 230000007812 deficiency Effects 0.000 claims description 52
- 208000011580 syndromic disease Diseases 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 38
- 230000006378 damage Effects 0.000 claims description 31
- 208000035475 disorder Diseases 0.000 claims description 29
- 102000014461 Ataxins Human genes 0.000 claims description 22
- 108010078286 Ataxins Proteins 0.000 claims description 22
- 208000014644 Brain disease Diseases 0.000 claims description 22
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 22
- 208000032274 Encephalopathy Diseases 0.000 claims description 22
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 22
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 22
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 22
- 208000002780 macular degeneration Diseases 0.000 claims description 22
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 20
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 19
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 19
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 19
- 239000000835 fiber Substances 0.000 claims description 19
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 19
- 208000017442 Retinal disease Diseases 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 17
- 230000000750 progressive effect Effects 0.000 claims description 17
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000030768 Optic nerve injury Diseases 0.000 claims description 16
- 206010038923 Retinopathy Diseases 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 16
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- 230000008733 trauma Effects 0.000 claims description 14
- LNOVHERIIMJMDG-KTWAZNHYSA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-KTWAZNHYSA-N 0.000 claims description 13
- 208000012268 mitochondrial disease Diseases 0.000 claims description 12
- 230000004770 neurodegeneration Effects 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 201000004569 Blindness Diseases 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 11
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 11
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 11
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 11
- 230000004393 visual impairment Effects 0.000 claims description 11
- 208000027073 Stargardt disease Diseases 0.000 claims description 10
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 10
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000026072 Motor neurone disease Diseases 0.000 claims description 8
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 208000035965 Postoperative Complications Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 238000002647 laser therapy Methods 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 208000021090 palsy Diseases 0.000 claims description 8
- 238000002428 photodynamic therapy Methods 0.000 claims description 8
- 208000032253 retinal ischemia Diseases 0.000 claims description 8
- 102000007371 Ataxin-3 Human genes 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000011476 stem cell transplantation Methods 0.000 claims description 7
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 5
- SFVAYPRWECRHTF-QRCIITMISA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=CC(=O)C=C(C)C1=O SFVAYPRWECRHTF-QRCIITMISA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 5
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 5
- 239000011723 β-tocotrienol Substances 0.000 claims description 5
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 5
- 208000006136 Leigh Disease Diseases 0.000 claims description 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 208000001749 optic atrophy Diseases 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003732 agents acting on the eye Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940113601 irrigation solution Drugs 0.000 claims description 2
- 229940125702 ophthalmic agent Drugs 0.000 claims description 2
- 229930003802 tocotrienol Natural products 0.000 claims description 2
- 239000011731 tocotrienol Substances 0.000 claims description 2
- 235000019148 tocotrienols Nutrition 0.000 claims description 2
- 229940064063 alpha tocotrienol Drugs 0.000 claims 3
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims 3
- 235000019145 α-tocotrienol Nutrition 0.000 claims 3
- 239000011730 α-tocotrienol Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000010444 Acidosis Diseases 0.000 claims 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 34
- 208000024891 symptom Diseases 0.000 description 7
- 208000027993 eye symptom Diseases 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000000642 iatrogenic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 3
- 208000018769 loss of vision Diseases 0.000 description 3
- 231100000864 loss of vision Toxicity 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000019150 γ-tocotrienol Nutrition 0.000 description 3
- 239000011722 γ-tocotrienol Substances 0.000 description 3
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21479509P | 2009-04-28 | 2009-04-28 | |
| US61/214,795 | 2009-04-28 | ||
| US31873710P | 2010-03-29 | 2010-03-29 | |
| US61/318,737 | 2010-03-29 | ||
| PCT/US2010/032621 WO2010126909A1 (en) | 2009-04-28 | 2010-04-27 | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235405A Division JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525397A JP2012525397A (ja) | 2012-10-22 |
| JP2012525397A5 true JP2012525397A5 (https=) | 2013-07-11 |
Family
ID=42236620
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508606A Withdrawn JP2012525397A (ja) | 2009-04-28 | 2010-04-27 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2014235405A Withdrawn JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2016078793A Pending JP2016128523A (ja) | 2009-04-28 | 2016-04-11 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2017152470A Pending JP2017193594A (ja) | 2009-04-28 | 2017-08-07 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014235405A Withdrawn JP2015038154A (ja) | 2009-04-28 | 2014-11-20 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2016078793A Pending JP2016128523A (ja) | 2009-04-28 | 2016-04-11 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| JP2017152470A Pending JP2017193594A (ja) | 2009-04-28 | 2017-08-07 | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100273892A1 (https=) |
| EP (1) | EP2424494A1 (https=) |
| JP (4) | JP2012525397A (https=) |
| BR (1) | BRPI1013377A2 (https=) |
| CA (1) | CA2759984A1 (https=) |
| EA (1) | EA201101576A1 (https=) |
| MX (1) | MX2011011310A (https=) |
| WO (1) | WO2010126909A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EP2471530B1 (en) * | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) * | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| WO2009158348A1 (en) * | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| CN102548548B (zh) * | 2009-06-10 | 2017-09-01 | 米拓科技有限公司（卢森堡） | 用于医学和兽医学的眼科药物组合物 |
| DK2470168T3 (en) * | 2009-08-26 | 2018-05-07 | Bioelectron Tech Corp | PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM |
| US20110172312A1 (en) * | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| AU2011238525A1 (en) * | 2010-04-06 | 2012-11-08 | Edison Pharmaceuticals, Inc. | Treatment of Ataxia Telangiectasia |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012167236A1 (en) | 2011-06-03 | 2012-12-06 | Mitotech Sa | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) * | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| US20150057363A1 (en) * | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| EP2573063A1 (en) | 2011-09-23 | 2013-03-27 | DSM IP Assets B.V. | Process for preparing chiral quinone |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| WO2015183963A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US20190365705A1 (en) * | 2017-01-20 | 2019-12-05 | Ohio State Innovation Foundation | Topical tocotrienol compositions and methods of increasing skin stem cells |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
| WO2024259130A1 (en) * | 2023-06-16 | 2024-12-19 | Ptc Therapeutics, Inc. | Methods for increasing vatiquinone plasma exposure with food |
| WO2025024247A1 (en) * | 2023-07-21 | 2025-01-30 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
| DE60211875T2 (de) * | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| US7015243B2 (en) * | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| WO2005033092A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| US20050074447A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Treatment for diabetic microvascular and macrovascular complications |
| JP5129563B2 (ja) * | 2004-03-18 | 2013-01-30 | ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト | 視神経症に対する感受性を診断または予測するための方法 |
| EP2471530B1 (en) * | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) * | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2008157747A1 (en) * | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
-
2010
- 2010-04-27 JP JP2012508606A patent/JP2012525397A/ja not_active Withdrawn
- 2010-04-27 EA EA201101576A patent/EA201101576A1/ru unknown
- 2010-04-27 WO PCT/US2010/032621 patent/WO2010126909A1/en not_active Ceased
- 2010-04-27 MX MX2011011310A patent/MX2011011310A/es not_active Application Discontinuation
- 2010-04-27 EP EP10715649A patent/EP2424494A1/en not_active Withdrawn
- 2010-04-27 CA CA2759984A patent/CA2759984A1/en not_active Abandoned
- 2010-04-27 BR BRPI1013377A patent/BRPI1013377A2/pt not_active Application Discontinuation
- 2010-04-27 US US12/768,554 patent/US20100273892A1/en not_active Abandoned
-
2013
- 2013-01-10 US US13/738,827 patent/US20140031433A1/en not_active Abandoned
-
2014
- 2014-11-20 JP JP2014235405A patent/JP2015038154A/ja not_active Withdrawn
-
2016
- 2016-04-11 JP JP2016078793A patent/JP2016128523A/ja active Pending
-
2017
- 2017-08-07 JP JP2017152470A patent/JP2017193594A/ja active Pending
- 2017-12-20 US US15/849,557 patent/US20180116978A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525397A5 (https=) | ||
| JP2012525398A5 (https=) | ||
| JP2012525399A5 (https=) | ||
| SI2424495T1 (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| AU2011245384B2 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| AU2011245384B9 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| CA2760357A1 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
| JP2013525443A5 (https=) | ||
| JP2017193594A (ja) | 眼科疾患を治療するためのトコトリエノールキノンの製剤 | |
| JP5345744B1 (ja) | 網膜疾患の予防、改善、又は治療剤 | |
| CA2801145A1 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| JP6867288B2 (ja) | リファマイシンの眼科用組成物およびその使用 | |
| JP6820658B2 (ja) | ジピリダモールを用いる眼疾患の治療において使用するための組成物 | |
| US10226444B2 (en) | Tissue repair of the nasal mucosa and treatment of rhinitis with alpha-tocpherol compositions | |
| ES3034599T3 (en) | Water-soluble topical ophthalmic preparation containing lutein and production method thereof | |
| Li et al. | Chinese expert consensus on perioperative medication in laser corneal refractive surgeries (2019) | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| IT201700022522A1 (it) | Composizione oftalmica per l’uso nella rigenerazione delle fibre nervose della cornea in soggetti che sono stati sottoposti ad un intervento di cheratoplastica | |
| Qamar et al. | Supratarsal injection of triamcinolone for vernal keratoconjunctivitis | |
| Pasyechnikova et al. | Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach | |
| Richter et al. | Age-related macular degeneration | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
| IT202100005777A1 (it) | Composizione per l’uso nel trattamento dell’occhio secco |